Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks From the Dupilumab Italian Prurigo Nodularis Study

    April 2026 in “ Clinical and Experimental Dermatology ”
    Marina Talamonti, Edoardo Mortato, Alessandra Narcisi, Silvia Mariel Ferrucci, Luigi Gargiulo, Angelo Valerio Marzano, Maddalena Napolitano, Cataldo Patruno, Mariateresa Rossi, Anna Balato, Niccolò Gori, Caterina Foti, Rossana Tiberio, Monica Corazza, Andrea Carugno, Laura Calabrese, Elena Pezzolo, Maria Esposito, Emiliano Antiga, Ilaria Trave, Paola Savoia, Francesca Caroppo, Martina Maurelli, Maria Letizia Musumeci, Paolo Amerio, Luca Stingeni, Serena Lembo, Rosanna Satta, Filomena Russo, Maria MARIANO, Claudia Paganini, Antonio Costanzo, Martina Zussino, M. Gaudio, Erica Stevan, Stefano Caccavale, Alessandra D’Amore, Benedetta Tirone, Ginevra Pertusi, Alessandro Borghi, Laura Lazzeri, Lina Maria Magnanimi, Roberto Maglie, Emanuele Cozzani, Federica Veronese, Anna Belloni Fortina, Giampiero Girolomoni, Giuseppe Micali, Edvige Morea, Katharina Hansel, Annunziata Raimondo, Gabriele Biondi, Donatella Sordi, Luciano Ibba, Maddalena Nicoletti, Ketty Peris, Giorgia Sbarra, Natale Schettini, Alessia Loda, Elia Esposto, Barbara Cocuroccia, Maria Concetta Fargnoli, Nicola Zerbinati, Luca Bianchi, Marco Galluzzo
    TLDR Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.
    The Dupilumab Italian Prurigo Nodularis (DUPItaPN) study evaluated the long-term effectiveness and safety of dupilumab in 543 adults with prurigo nodularis (PN) over 104 weeks. The study found that dupilumab significantly improved symptoms, with the mean Worst Itch Numeric Rating Scale (WI-NRS) score decreasing from 8.7 to 1.7, and 86.8% of patients achieving a ≥4-point reduction by week 104. Additionally, 81.2% of patients reached an Investigator Global Assessment for PN-Stage (IGA PN-S) of 0/1. The Dermatology Life Quality Index (DLQI) improved from 17.4 to 2.6. Dupilumab was well tolerated, with only 2.9% discontinuing due to adverse events, and no cancer progression or viral reactivation observed. The study supports dupilumab as a long-term treatment option for moderate-to-severe PN, even in elderly and comorbid patients.
    Discuss this study in the Community →